Dermorphin

Dermorphin

Dermorphin is a naturally occurring heptapeptide and a remarkably potent, highly selective agonist of the μ‑opioid receptor (MOR)—the primary receptor subtype mediating classical opioid analgesia and many neuromodulatory effects. Isolated from the skin of South American Phyllomedusa tree frogs, Dermorphin has the sequence H‑Tyr‑D‑Ala‑Phe‑Gly‑Tyr‑Pro‑Ser‑NH₂. Its defining structural feature is a D‑alanine at position 2, an uncommon stereochemical configuration in natural peptides that greatly enhances resistance to enzymatic degradation and significantly increases binding affinity and functional potency at MOR.

Because of its strong μ‑selectivity, high intrinsic efficacy, and prolonged duration of action in experimental systems, Dermorphin is widely employed as a research tool to study opioid receptor pharmacology, nociceptive signaling, and G‑protein–coupled receptor (GPCR) mechanisms.

Dermorphin from Montreal Peptides Canada is supplied as a high‑purity, lyophilized peptide for laboratory and scientific research use only. It is not intended or approved for human or veterinary administration, diagnosis, treatment, or consumption.

Dermorphin Overview

Dermorphin combines a compact peptide backbone with an unusual D‑amino acid configuration, leading to a distinctive pharmacologic profile:

• Sequence: H‑Tyr‑D‑Ala‑Phe‑Gly‑Tyr‑Pro‑Ser‑NH₂
• Key feature: D‑Ala at position 2 (rare in natural peptides)
• Functional impact: Elevated MOR affinity, enhanced metabolic stability, and extended bioactivity

Relative to classical opioid ligands such as morphine and endogenous peptides like β‑endorphin, Dermorphin:

• Exhibits substantially higher potency at the μ‑opioid receptor
• Demonstrates strong selectivity for MOR over κ‑ and δ‑opioid receptor subtypes
• Displays slow dissociation kinetics, resulting in sustained receptor occupancy and signaling

Upon MOR activation, Dermorphin initiates the canonical inhibitory GPCR cascade:

• Inhibition of adenylate cyclase with reduction of intracellular cAMP
• Modulation of ion channel activity (decreased Ca²⁺ influx, increased K⁺ conductance)
• Suppression of neurotransmitter release at presynaptic terminals

These actions underlie its pronounced antinociceptive and sedative effects in experimental models and make Dermorphin a valuable probe for dissecting μ‑opioid receptor function.

Dermorphin Structure

Chemical Makeup

• Molecular Formula: C₄₀H₅₀N₈O₁₀
• Molecular Weight: 802.88 Da
• Observed Mass (Batch #2025034): 802.9 Da
• Purity: 99.09% (HPLC and LCMS confirmed)
• Form: Lyophilized powder
• Analytical Methods:
• Reverse‑phase HPLC (UV detection at 214 nm)
• LCMS (ESI⁺ mode), calibrated against a synthetic Dermorphin reference standard
• Appearance: White to off‑white crystalline powder

Dermorphin Research

μ‑Opioid Receptor Binding and Selectivity

Dermorphin is considered a reference natural ligand for μ‑opioid receptor studies:

• High‑affinity MOR agonist: Radioligand binding and competition assays consistently show low‑nanomolar to subnanomolar affinity for MOR.
• Selective μ‑profile: It has markedly reduced activity at κ‑ and δ‑opioid receptors, allowing relatively clean assessment of μ‑mediated actions.
• Stable receptor engagement: Slow off‑rates at MOR support prolonged receptor activation and sustained downstream signaling.

These characteristics make Dermorphin well suited for:

• Structural studies of MOR–ligand interaction and binding pocket characterization
• Comparative analysis of binding kinetics, efficacy, and receptor activation among opioid ligands
• Investigations into the molecular basis of μ‑selectivity vs. other opioid receptor subtypes

Analgesic Mechanisms

In experimental pain models, Dermorphin serves as a powerful tool for probing μ‑opioid–mediated antinociception:

• High‑potency analgesia: Dermorphin often produces stronger and longer‑lasting analgesic responses than morphine when compared on a molar basis.
• Prolonged action: The D‑Ala residue substantially improves resistance to peptidase degradation, extending functional activity and MOR engagement.
• Chronic exposure paradigms: Its sustained effect makes Dermorphin suitable for studying tolerance development, changes in receptor sensitivity, and adaptations within nociceptive pathways after repeated μ‑receptor activation.

These features support research into both therapeutic aspects (analgesia) and adaptive responses (tolerance, dependence) associated with sustained opioid receptor stimulation.

Neurochemical and Behavioral Studies

Dermorphin is also widely used in neurochemical and behavioral research to explore opioid‑mediated neuromodulation:

• Synaptic effects: It modulates release of key neurotransmitters and neuromodulators, including glutamate, GABA, and monoamines, thereby altering synaptic strength in circuits governing pain, reward, and affect.
• Neuronal excitability: Through MOR‑dependent ion channel regulation, Dermorphin influences firing patterns and excitability of neurons in the spinal cord and brain regions such as the periaqueductal gray and limbic structures.
• GPCR signaling and plasticity: Dermorphin serves as a model agonist for studying G‑protein vs. β‑arrestin signaling bias, receptor desensitization and internalization, and long‑term synaptic and cellular adaptations following repeated μ‑receptor activation.

These applications help clarify how μ‑opioid signaling shapes cellular, circuit‑level, and behavioral responses relevant to nociception, reward processing, and opioid‑induced neuroplasticity.

Article Author

This literature overview is presented in recognition of the seminal work of Dr. Vittorio Erspamer, M.D., Ph.D. Dr. Erspamer was a pioneering Italian pharmacologist and biochemist whose research led to the discovery and characterization of numerous bioactive peptides from amphibian skin, including dermorphin, deltorphin, and bombesin. His isolation, structural elucidation, and pharmacological analysis of Dermorphin established it as a landmark natural μ‑opioid receptor agonist and significantly advanced the fields of neuropharmacology, peptide chemistry, and peptide‑based therapeutic research.

Scientific Journal Author

The discovery and early pharmacological characterization of Dermorphin were achieved through the collaborative efforts of Dr. Vittorio Erspamer and colleagues P.C. Montecucchi, R. De Castiglione, S. Piani, L. Gozzini, and M. Broccardo. Their foundational studies:

• Identified Dermorphin as a novel amphibian peptide with potent opiate‑like activity
• Determined its primary structure and confirmed the presence of D‑Ala
• Demonstrated its high potency and selectivity as a μ‑opioid receptor agonist in central and peripheral preparations

Subsequent work by researchers such as L. Negri, G. Lazzeri, C.H. Li, and D. Chung further refined understanding of Dermorphin’s receptor‑binding characteristics, analog design, and structure–activity relationships.

This acknowledgment is provided solely to recognize the scientific contributions of Dr. Erspamer and collaborators. It does not imply endorsement, sponsorship, or formal affiliation between Montreal Peptides Canada and any researchers or institutions cited.

Reference Citations

1. Montecucchi PC, De Castiglione R, Piani S, Gozzini L, Erspamer V. A novel amphibian skin peptide with potent opiate-like activity. Nature. 1981;292(5826):608–610. https://pubmed.ncbi.nlm.nih.gov/7198101/
2. Erspamer V, et al. Dermorphin: a potent natural analgesic peptide from amphibian skin. Eur J Pharmacol. 1982;78(3):337–342. https://pubmed.ncbi.nlm.nih.gov/6288442/
3. Negri L, et al. Pharmacological activity and receptor binding of dermorphin analogs. Peptides. 1985;6(Suppl 3):87–91. https://pubmed.ncbi.nlm.nih.gov/2413894/
4. Broccardo M, et al. Central and peripheral activity of dermorphin in animal models. Br J Pharmacol. 1981;73(3):625–631. https://pubmed.ncbi.nlm.nih.gov/6264952/
5. Li CH, Chung D. Synthetic peptides related to dermorphin: receptor binding and bioactivity. Biochemistry. 1983;22(8):1923–1928. https://pubmed.ncbi.nlm.nih.gov/6300120/
6. Lazzeri G, Negri L, et al. Receptor selectivity of dermorphin analogues. Eur J Pharmacol. 1985;110(3):357–363. https://pubmed.ncbi.nlm.nih.gov/2988703/
7. Stefano GB, et al. Opiate receptor activity in invertebrate and vertebrate systems: insights from dermorphin analogues. Proc Natl Acad Sci U S A. 1989;86(22):8977–8981. https://pubmed.ncbi.nlm.nih.gov/2573076/
8. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev. 2001;81(1):299–343. https://pubmed.ncbi.nlm.nih.gov/11152759/
9. DrugBank Online. Dermorphin. https://go.drugbank.com/drugs/DB13355
10. National Center for Biotechnology Information. Dermorphin compound summary. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Dermorphin

HPLC/MS

HPLC

Dermorphin purity is determined by reverse‑phase high‑performance liquid chromatography (RP‑HPLC) with UV detection at 214 nm. The chromatogram shows a single predominant peak corresponding to Dermorphin, with total impurities below 1%. The measured purity of 99.09% meets the standards expected for high‑quality research‑grade peptides.

MS

Mass spectrometric analysis (LCMS, ESI⁺ mode) confirms the expected molecular ion for Dermorphin, with an observed mass of approximately 802.9 Da, in excellent agreement with the theoretical molecular weight of 802.88 Da. No significant additional peaks corresponding to major truncations, oxidation products, or sequence variants are detected within the sensitivity limits of the method.

STORAGE

Storage Instructions

All peptide products are manufactured by lyophilization (freeze‑drying), which maintains stability for shipping and short‑term handling (approximately 3–4 months). After reconstitution with bacteriostatic water:

• Store the peptide solution at ~4°C (39°F).
• Under these conditions, most peptide solutions remain stable for up to 30 days.

Lyophilization (cryodesiccation) involves freezing the peptide and applying low pressure so that water sublimes directly from solid to gas, leaving a stable dry powder. This lyophilized material can generally be stored at room temperature for shorter periods prior to reconstitution.

For long‑term storage (several months to years):

• Store lyophilized peptides at −80°C (−112°F).
• Protect vials from light and moisture to preserve structural integrity and biological activity.

Upon receipt, peptides should be promptly moved to a cold, dark storage environment. For near‑term use (days to a few months), refrigeration below 4°C (39°F) is usually sufficient; lyophilized peptides typically remain stable at room temperature for several weeks.

Best Practices For Storing Peptides

To maintain peptide integrity and experimental reliability:

• Keep peptides cool, dry, and protected from light immediately upon arrival.
• Use refrigeration (≤4°C / 39°F) for short‑ to medium‑term storage.
• Use −80°C (−112°F) freezers for long‑term preservation.
• Avoid frost‑free freezers, which undergo periodic warming cycles.
• Minimize freeze‑thaw cycles, as repeated temperature fluctuations accelerate degradation.

Following these best practices significantly extends peptide shelf life and helps preserve purity and bioactivity.

Preventing Oxidation and Moisture Contamination

To reduce oxidative and hydrolytic degradation:

• Allow frozen vials to reach room temperature before opening to prevent condensation.
• Keep vials tightly sealed, opening them only long enough to retrieve the required amount.
• When feasible, store remaining peptide under a dry, inert gas atmosphere (e.g., nitrogen or argon).

Peptides containing cysteine (C), methionine (M), or tryptophan (W) residues are especially susceptible to oxidation and should be handled with additional care. To limit repeated exposure to air and temperature shifts, divide bulk peptide into small aliquots for single or limited experimental use.

Storing Peptides In Solution

Peptide solutions are more labile than lyophilized powders and more prone to hydrolysis and contamination:

• Use sterile buffers with a pH in the range of 5–6 when possible.
• Prepare aliquots to avoid multiple freeze‑thaw cycles.
• At 4°C (39°F), most peptide solutions remain stable for up to 30 days.
• For more unstable peptides, maintain solutions frozen when not in immediate use.

Whenever practical, keep peptides lyophilized and reconstitute only shortly before use.

Peptide Storage Containers

Container selection also contributes to peptide stability:

• Use clean, chemically inert vials appropriately sized to minimize headspace.
• Glass vials offer excellent chemical resistance and optical clarity.
• Plastic vials (polystyrene or polypropylene) are also suitable:
• Polystyrene: clear and easy to inspect, but less chemically resistant
• Polypropylene: more chemically robust, typically translucent

Peptides are often shipped in plastic containers to reduce breakage risk and can be transferred to glass or alternative vials as needed, provided that handling is clean and contamination‑free.

Peptide Storage Guidelines: General Tips

To preserve peptide quality over time:

• Store in a cold, dry, dark environment.
• Avoid repeated freeze‑thaw cycles.
• Minimize exposure to air to limit oxidation.
• Protect from direct and prolonged light.
• Prefer lyophilized storage for long‑term keeping; do not store in solution long term.
• Aliquot peptides based on experimental requirements to reduce unnecessary handling and environmental exposure.